Cargando…
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transfor...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817862/ https://www.ncbi.nlm.nih.gov/pubmed/33521700 http://dx.doi.org/10.1016/j.xcrm.2020.100186 |